247034-07-7

Upstream product

• 451-46-7 4-fluorobenzoic acid ethyl ester 
• 247035-14-9 ethyl 4-[4-[{N-methyl-N-(pyrimidin-2-yl)}amino]piperidin-1-yl]benzoate 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 247035-15-0 4-[4-[{N-methyl-N-(pyrimidin-2-yl)}amino]piperidin-1-yl]benzoic acid 
• 247034-88-4 ethyl 4-(4-aminopiperidin-1-yl)benzoate 
• 25437-94-9 ethyl 4-(4-hydroxypiperidin-1-yl)benzoate 
• 247034-87-3 ethyl 4-(4-phthalimidopiperidin-1-yl)benzoate 
• 247034-89-5 ethyl 4-{4-(pyrimidin-2-ylamino)piperidin-1-yl}benzoate 

Relevant academic research and scientific papers

Tricyclic pharmacophore-based molecules as novel integrin αvβ3 antagonists. Part 1: Design and synthesis of a lead compound exhibiting αvβ3/ αIIbβ3 dual antagonistic activity

In order to generate novel compounds with integrin α vβ3-antagonistic activity together with antiplatelet activity, tricyclic pharmacophore-based molecules were designed and synthesized. Although piperazine-containing compounds initially prepared were selective αIIbβ3 antagonists, replacement of piperazine with piperidine furnished a potent αvβ3/ αIIbβ3 dual antagonist. Structure-activity relationship (SAR) studies provided clues for further development of tricyclic pharmacophore-based integrin antagonists.